TABLE 1.
Clinical data on 61 robotic surgeries performed during COVID‐19 pandemic
| Parameter, unit | Value |
|---|---|
| Patient factors | |
| Age, years, median (IQR) | 68 (63–73) |
| Male gender, n (%) | 53 (86.9%) |
| ASA score, n (%) | |
| 1 | 6 (9.8%) |
| 2 | 34 (55.7%) |
| 3 | 21 (34.4%) |
| COVID‐19 risk factors, n (%) | |
| 0 | 1 (1.6%) |
| 1 | 11 (18%) |
| 2 | 21 (34.4%) |
| 3 | 15 (24.6%) |
| 4 | 9 (14.8%) |
| 5 | 3 (4.9%) |
| 6 | 1 (1.6%) |
| Surgery data | |
| Type of surgery, n (%) | |
| Robot‐assisted radical prostatectomy | 37 (60.7%) |
| Robot‐assisted partial nephrectomy | 14 (23%) |
| Robot‐assisted pyeloplasty | 3 (4.9%) |
| Robot‐assisted radical cystectomy | 2 (3.3%) |
| Robot‐assisted radical nephroureterectomy | 2 (3.3%) |
| Robot‐assisted adrenalectomy | 1 (1.6%) |
| Robot‐assisted simple prostatectomy | 1 (1.6%) |
| Robot‐assisted super‐extended lymphadenectomy | 1 (1.6%) |
| OR time, minutes, median (Q1–Q3) | 171 (138–198) |
| Preoperative COVID‐19 screening, n (%) | |
| COVID‐19 screening form | 46 (75.4%) |
| COVID‐19 swab | 21 (34.4%) |
| Intraoperative adverse events (EAUiaiC), n (%) | |
| None | 54 (90.2%) |
| Grade 1 | 3 (4.9%) |
| Grade 2 | 2 (3.3%) |
| Grade 3 | 1 (1.6%) |
| Grade 4 | 0 (0%) |
| Grade 5 | 0 (0%) |
| Postoperative complications within 7 days, Clavien‐Dindo, n (%) | |
| None | 42 (68.9%) |
| Grade 1 | 10 (16.4%) |
| Grade 2 | 2 (3.3%) |
| Grade 3 | 5 (8.2%) |
| Grade 4 | 2 (3.3%) |
| Postoperative COVID‐19 infection | |
| Follow‐up period, days, median (Q1–Q3) | 48 (28–60) |
| Proven COVID‐19 infection, n (%) | 1 (1.6%) |
| COVID‐19 swab test performed, negative result, n (%) | 6 (9.8%) |